Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(319)
•••
Comment by Claridgeon Oct 10, 2019 5:12pm
204 Views
Post# 30219486

RE:RE:Drug/Device combination technology 1-2-3

RE:RE:Drug/Device combination technology 1-2-3
June 2019 -

Theralase has a patented Study Drug and Study Device that when combined, have proven to be safe and effective in the treatment of patients inflicted with Bacillus Calmette Gurin-Unresponsive NMIBC.


It's a FDA/CE category

May 2019 - Guideline on the quality requirements for drug-device combinations

https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-requirements-drug-device-combinations_en.pdf


Johnson&Johnson also has similar concept ...

April 2019 ... https://pqri.org/wp-content/uploads/2019/04/1-PQRI-FDA-Conference-Day-1-Track-2-Session-3-Neadle.pdf


And you can also find more here:

Drug-Device Combination Products - 1st Edition - Elsevier


https://www.elsevier.com › books › lewis
 

The book will provide a thorough analysis of the fundamentals, applications and new technologies of drug-device combination products for use throughout the ...


Drug/Medical Device Combination Products - Canada.ca


https://www.canada.ca › drug-products › policies › dru...

 
30 nov. 2005 - The purpose of this policy is to ensure timely access to drug/medical device combination products by establishing a single window approach ...

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities